The allergy vaccine sector is in good shape, with companies investing in and testing new approaches, some consolidation among allergy-focused firms, and a desire among companies to “go global” and to break out of their European strongholds, says Manuel Llobet, CEO of Allergy Therapeutics PLC, a rapidly growing UK-based allergy company.
The sector may have been stunned by the recent failure of Circassia Pharmaceuticals PLC’s investigational cat allergy product, Cat-SPIRE,...